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Subclinical hypothyroidism and 
risk to carotid atherosclerosis
Hipotireoidismo subclínico e risco de aterosclerose carotídea
Velkoska Nakova Valentina1, Bosevski Marijan2, 
Dimitrovski Chedo3, Krstevska Branka3
ABSTRACT
Objective: The aim of this study was to assess whether subclinical hypothyroidism (SCH) is 
associated with carotid atherosclerosis, as well as dyslipidemia, and arterial hypertension. 
Subjects and methods: The study included 69 consecutive patients with newly diagnosed 
SCH, and 30 matched healthy controls. Body mass index (BMI), TSH, fT4, antibodies to thyroid 
peroxidase (TPOabs), lipids, blood pressure, mean and maximum carotid intima-media thick-
ness (CIMT) were determined in all participants. Results: Mean values of CIMT, triglycerides, 
and total cholesterol/HDL-C ratio were significantly different in SCH patients versus matched 
controls. Linear multiple regression analysis demonstrated that TSH, diastolic blood pressure 
and triglycerides were independent predictors of mean CIMT, fT4 for maximum CIMT; and that 
TSH, fT4, age, and total cholesterol/HDL-C ratio were independent predictors of the presence of 
carotid plaques. Conclusion: Our data revealed that SCH is associated with increase in CIMT 
and presence of carotid plaques, independent of classical risk factors for atherosclerosis. Arq 
Bras Endocrinol Metab. 2011;55(7):475-80
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ReSumo
Objetivo: O objetivo deste estudo foi avaliar se o hipotireoidismo subclínico (HSC) está as-
sociado a aterosclerose de carótida, dislipidemia e hipertensão arterial. Sujeitos e métodos: 
O estudo incluiu 69 pacientes consecutivos recém-diagnosticados com HSC e 30 controles 
pareados. Índice de massa corpórea, TSH, T4L, anticorpos antiperoxidase (TPO), perfil lipídico, 
pressão arterial, espessamento carotídeo íntima-média máximo (ECIM) e médio foi determina-
do em todos os indivíduos. Resultados: Os valores médios de ECIM, triglicérides e razão co-
lesterol total/C-HDL foram significantemente diferentes entre pacientes e controles. Regressão 
linear múltipla demonstrou que TSH, pressão arterial diastólica e triglicérides foram fatores 
independentes preditores de ECIM médio, T4L para ECIM máximo e TSH, T4L, idade e colesterol 
total/HDL-C para presença de placa carotídea. Conclusão: Nossos resultados indicam que HSC 
é associado com aumento do ECIM e presença de placas carotídeas, independentemente dos 
fatores de risco clássicos para aterosclerose. Arq Bras Endocrinol Metab. 2011;55(7):475-80
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INTRoDuCTIoN
Subclinical hypothyroidism (SCH) is a common condi-tion affecting 4%-20% of the general population. SCH 
is defined as increased serum thyrotropin (TSH) concen-
trations and normal serum free thyroxine levels (fT4) (1). 
Patients with primary hypothyroidism are at a 
three times greater risk for early atherosclerosis, as 
shown independently for other risk factors, such as 
atherogenic lipid profile, hypertension and impaired 
endothelial function. Whether SCH has influence on 
the same risk factors and is associated with atherosclero-
sis is still under debate (2). Some studies showed that 
there is an association (3-5), but others did not (6,7). 
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Because of these controversies, the benefit from 
thyroid replacement therapy in SCH is unclear. 
The carotid intima-media thickness (CIMT) is used 
as a parameter for determining current subclinical athe-
rosclerotic changes. Carotid plaques have been shown to 
be independent predictors of future vascular events (8,9). 
If SCH is associated with greater CIMT and carotid pla-
ques, thyroid hormone replacement therapy is required. 
The aim of this study was to assess whether SCH is 
associated with carotid atherosclerosis, as measured by 
the increase in CIMT and presence of plaques. 
mATeRIALS AND meTHoDS
Patients
At the Department of Endocrinology Diabetes and 
Metabolic Disorders, Skopje, R. Macedonia, 69 con-
secutive patients with newly diagnosed SCH were exa-
mined. The criteria for SCH were: normal fT4 (10.3-
24.45 pmol/L) and elevated TSH (4.2<TSH<20.0 
mU/L) serum levels in at least two thyroid function 
tests measured no less than two weeks apart (10). Thir-
ty healthy, euthyroid subjects, defined as patients with 
reference values  of fT4 and TSH (0.2-4.2 mU/L), 
were included in the study as a control group. None 
of the patients had a previous history of thyroid dise-
ase, arterial hypertension, or took any medication for 
thyroid disease, arterial blood pressure or lipid meta-
bolism. Patients with diabetes mellitus, liver or renal 
disease, chronic pancreatitis, primary hyperlipidemia, 
ovulatory dysfunction, pregnancy and infertility were 
excluded from the study. 
Body mass index (BMI), TSH, fT4, TPOabs, total 
lipids, total cholesterol, high-density lipoprotein cho-
lesterol (HDL-C), low-density lipoprotein cholesterol 
(LDL-C), triglycerides, blood pressure, mean and ma-
ximum carotid intima-media thickness (CIMT and max 
CIMT) were determined in all participants. 
meTHoDS
Laboratory analysis 
Blood samples were drawn at 8 am, after a 14-hour fast. 
Blood samples for lipoproteins were analyzed using 
Cobas Integra 700, according to standard methods. 
Total cholesterol and triglycerides were determined by 
full enzymatic methods (TH-CHOD-POD-PAP and 
triglycerides-GPO; Cobas Integra 700, Hoffmann-La 
Roche, Basel, Switzerland). HDL-C was measured by 
the polyanion precipitation method, while LDL-C was 
calculated using the Friedewald formula. LDL-C were 
fractioned using ultracentrifugation in cases, when tri-
glycerides exceeded 4 mmol/L. Serum TSH and free 
T4 concentrations were measured using an Immulite 
2000 chemiluminescent analyzer (Siemens Medical So-
lutions Diagnostics, Los Angeles, CA, USA). The sen-
sitivity of the assays was 0.004 μU/mL and 0.3 ng/
dL, respectively. TPOabs was determined by the immu-
nometric assay from Diagnostic Products Corporation 
(Los Angeles, CA). For positive TPOabs, values over 
34 IU/mL were obtained. 
measurement of blood pressure, height, and body 
weight
Blood pressure was measured twice on the right hand, 
with a desk-model sphygmomanometer after five mi-
nutes at rest in a sitting position. There was a 3-min in-
terval between the two measurements for each patient, 
and the mean value of the two measurements was used. 
In the case of hypertension (≥ 140/90 mmHg), the 
measurement was repeated after 5 minutes.
Patients were weighed without clothes and shoes on 
an electronic scale, in the morning fasting. Their hei-
ght was measured to the nearest cm with a stadiometer. 
Body mass index (BMI) was calculated as body weight 
(in kg) divided by the square of body height (in meters).
Carotid ultrasound 
The risk for atherosclerosis was estimated by the ul-
trasound system HP Agilent S4500. To avoid varia-
tions, the examination was performed by the same 
experienced physician, who was blind to the patients’ 
risk factors. Mean and maximum CIMT were deter-
mined by B-mode ultrasound using a linear trans-
ducer (7.5-10 MHz). These values were calculated 
as a mean value of two measurements on a segment 
free of plaque in the right common carotid artery. 
Plaque was defined as a localized thickened lesion 
(≥ 1.1 mm). The study protocol was based on the 
Mannheim consensus (11). Intra-observer variability 
was up to 6%, as previously published.
ethical aspects
All patients gave informed consent to participate in 
the study, after the research protocol was explained to 
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them. The study was carried out according to the De-
claration of Helsinki.
Statistical analysis
Statistical analyses were performed by SPSS 11.0. 
The t-test was used for the analysis of quantitative 
variables. χ2-test was used for the analysis of qualita-
tive variables. Multivariate analysis was done by put-
ting BMI, TSH, fT4, TPOabs, systolic and diastolic 
blood pressure, total lipids, triglycerides, total cho-
lesterol, HDL-C, LDL-C, total cholesterol/HDL-
-C, LDL-C/HDL-C, and age in the model.
ReSuLTS
In this study, 99 patients were analyzed. They were 42.8 
± 15.2 years old, and 10 were men and 89 women. The-
re were not any differences in age, gender, BMI, number 
of women in menopause, and smoking habits between 
the SCH and control group (Table 1, NS in all cases). 
Table 1. Personal and hormonal characteristics of the SCH and control group
  SCH groupn = 67
control group
n = 30 P value
Sex (m : f) 7 : 62 (10.1%) 3 : 27 (10%) NS
Age (years) 42.4 ± 16.2 43.6 ± 12.8 NS
BMI (kg/m2) 27.8 ± 5.6 25.4 ± 5.1 NS
Menopauses 18 (29%) 8 (29.6%) NS
Smoking 12 (17.4%) 5 (16.6%) NS
fT4 pmol/L 14.5 ± 2.8 15.7 ± 2.5 p = 0.04
TSH mu/L 7.9 ± 3.6 1.5 ± 0.8 p < 0.000001
anti-TPo 41/60 (68.3%) 3/24 (12.5%) p < 0.0001*
Results are presented as means ± std deviation and percentages. NS: no significance. * Chi-
square test, Yates correction factor.
Table 2. Differences in the variables analyzed in the SCH and control group
Variables SCH groupn = 67
control group
n = 30
t-test
p value
Total lipids (mmol/L) 8.71 ± 1.9 8.14 ± 1.5 0.19
Triglycerides (mmol/L) 1.70 ± 1.1 1.18 ± 0.6 0.016
Total cholesterol (mmol/L) 5.46 ± 1.3 5.20 ± 0.9 0.34
HDL-C (mmol/L) 1.33 ± 0.37 1.46 ± 0.38 0.12
LDL-C (mmol/L) 3.42 ± 1.09 3.33 ± 0.79 0.67
Total chol/HDL-C (mmol/L) 4.44 ± 1.60 3.76 ± 1.03 0.037
LDL-C/HDL-C (mmol/L) 2.78 ± 1.22 2.44 ± 0.87 0.17
Systolic pressure (mmHg) 128 ± 20.7 121.8 ± 16.5 0.11
Diastolic pressure (mmHg) 81.66 ± 12.3 78.6 ± 9.1 0.19
CImT (mm) 0.61 ± 0.1 0.56 ± 0.1 0.034
max CIMT (mm) 0.65 ± 0.1 0.64 ± 0.1 0.65
Results are presented as means ± standard deviation.
Free thyroxine was significantly lower in the SCH 
group. Prevalence of positive TPOabs was significantly 
higher in the SCH group (68.3% vs. 12.5%, p < 0.0001). 
Differences in lipid status and blood pressure 
between SCH and control group
Patients with SCH had significantly higher mean tri-
glycerides, and total cholesterol/HDL-C ratio. Serum 
concentration of total lipids, total cholesterol, HDL-C, 
LDL-C, and LDL-C/HDL-C ratio were not statisti-
cally significant. Mean systolic and diastolic blood pres-
sure were higher in the SCH group, but the differences 
were not statistically significant (Table 2). 
Differences in carotid intima-media thickness 
between SCH and control group
Patients with SCH had statistically significantly greater 
mean CIMT then the control group (Table 2, Figure 1). 
But maximum CIMT values between the groups were 
not statistically significant (Table 2). When we compa-
red the mean and maximum values of CIMT for men 
and women in the SCH group, we did not find statisti-
cally significant differences (Figure 2). 
Impact of TPoabs on risk factors for atherosclerosis
There was no statistically significant difference in mean 
values of lipids and blood pressure according to the 
presence of TPOabs in the SCH group. Those who had 
positive TPOabs had greater CIMT (0.61 ± 0.1 mm, 
vs. 0.56 ± 0.09 mm, p = 0.08), but the difference was 
not statistically significant.
Carotid atherosclerosis in SCH and control group
Carotid atherosclerosis was determined in both groups. 
Seven patients from SCH group and one from the con-
trol group had carotid plaques. Thus, SCH group had 
a greater prevalence of carotid plaques compared with 
the control group (10.1% vs. 3.3%). When age was con-
sidered, all patients from both groups with carotid pla-
ques were women.  
Multiple linear regression was used to determine the 
impact of risk factors as independent predictors on the de-
pendent variables mean CIMT, max CIMT, and carotid 
plaques. TSH, triglycerides and diastolic blood pressure 
were independent predictors of mean CIMT. While fT4 
was an independent predictor of max CIMT. TSH, fT4, 
age, and ratio of total cholesterol/HDL-C were indepen-
dent predictors of the presence of carotid plaques (Table 3). 
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1: SCH group, 2: control group.
Figure 1. Mean CIMT values in SCH and control group.
1: men; 2: women.
Figure 2. Mean CIMT values in men and women from SCH group.
Table 3. Influence of risk factors in mean and maximum CIMT, and 
presence of plaques
unstandardized 
Coefficients
Standardized 
Coefficients t Sig. 
B Std. error Beta
CImT
(Constant) .259 .106  2.441 .021
TSH .009 .004 .313 2.339 .026
Diastolic .004 .001 .537 2.871 .008
Triglycerides .059 .025 .434 2.310 .028
max CImT 
(Constant) .757 .267 2.841 .008
fT4 -.014 .006 -.391 -2.261 .032
Plaques
(Constant) 0.172 0.722 0.238 0.814
TSH 0.040 0.019 0.398 2.121 0.043
fT4 0.049 0.023 0.435 2.165 0.039
Age 0.012 0.004 0.567 2.718 0.011
Total hol/HDLC 0.116 0.051 0.522 2.258 0.032
The table shows only variables with predictive values.
In healthy patients, only age was an independent 
predictor of CIMT.
DISCuSSIoN
The results show that patients with SCH differ from 
healthy euthyroid individuals matched by sex, age, 
and BMI in the mean values  of triglycerides, athero-
genic ratio of total cholesterol/HDL-C, and mean 
CIMT. 
Several studies have shown an association between 
SCH and hypercholesterolemia (1, 12), but other 
studies have not (13-16). Even though TSH is su-
ggested as a major factor in the relationship between 
dyslipidemia and SCH, the present study did not 
confirm this finding. The reasons for the differen-
ces between these studies are not clear. Maybe the 
weak relationship between TSH and total choleste-
rol is responsible for these differences. The 1mU/L 
increase in TSH resulted in a 0.02 mmol/L increase 
in total cholesterol (12). The present study may re-
quire a larger group of patients to show statistical 
significance.
Monzani and cols. (17) and Nagasaki and cols. 
(18) showed increased CIMT in patients with SCH. 
Kim and cols. (19) showed a difference in total cho-
lesterol, LDL-C, and mean CIMT (0.66 ± 0.1 mm, 
vs. 0.57 ± 0.08 mm) in SCH, compared with healthy 
control groups. In the present study, CIMT differed 
significantly (0.61 ± 0.1 mm, vs. 0.56 ± 0.09 mm), 
although the difference was not as great as in the 
study by Kim and cols. (19). The difference of CIMT 
in the study of Kim and cols. (19) is perhaps due to 
differences in mean cholesterol between the groups. 
In the present study, there was no difference in mean 
total cholesterol, and SCH had a direct impact on 
CIMT, regardless of lipid status. But we should not 
ignore the fact that both groups differed in mean tri-
glycerides and total cholesterol/HDL-C ratio.
Plaque formation is an advanced stage of atheroscle-
rosis. Great prevalence of carotid plaques in the group 
with subclinical hypothyroidism shown in the present 
paper suggests that these patients have an increased 
risk of cardiovascular disease compared with healthy 
patients. Sex-specific differences in CIMT values and 
plaque prevalence were previously demonstrated. Men 
have greater CIMT and worse plaque profile (20). But 
in the present study, there was no difference in mean 
and maximum CIMT between men and women. The 
0,66
0,64
0,62
0,60
0,58CI
M
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prevalence of carotid plaques was higher in women 
than men. That is due to the lower number of men 
compared with women in the study, which is logical for 
thyroid diseases. 
Multiple linear regression analysis showed that 
TSH, triglycerides, and diastolic blood pressure 
are independent predictors of mean CIMT, while 
fT4 proved to be an independent predictor of max 
CIMT, which is similar to previous findings (21). As 
fT4 was significantly lower in the SCH group and 
negatively correlated with mean CIMT, and showed 
to be an independent predictor of max CIMT, lower 
fT4 is a risk factor for atherosclerosis, even when in 
reference range. This suggests that SCH is associated 
with increase in CIMT, independent of the influence 
of classical risk factors (age, hypertension, dyslipide-
mia), which was also shown in table 3. Even more 
TSH and fT4 were independent predictors for ca-
rotid plaques. Other studies confirmed that TSH in 
SCH patients is related with carotid atherosclerosis 
(22), and low fT4 may adversely affect cardiovascular 
risk due to its effect on CIMT (23).
Different mechanisms are involved in atheroscle-
rosis caused by SCH. Thyroid autoimmunity is one 
of these mechanisms. Hashimoto thyroiditis is the 
most common condition causing SCH. Recently, it 
has been shown that Hashimoto thyroiditis is res-
ponsible for chronic inflammation, which causes en-
dothelial dysfunction, a promoter of atherosclerosis. 
Abnormal immune response mediated by immune 
complex causes vascular damage (24). However, this 
mechanism is not sufficiently clear. We did not me-
asure markers of inflammation or oxidative stress to 
show that inflammation is responsible for the asso-
ciation between SCH and CIMT, nor for the etio-
logy of SCH. So it cannot be said that Hashimoto 
thyroiditis is the cause of SCH. But the presence of 
TPOabs was recorded. In the Rotterdam study (5) 
the incidence of atherosclerosis was higher in SCH 
in the presence of positive TPOabs. In this study, 
patients with positive TPOabs had greater CIMT 
(0.61 ± 0.1 mm, vs. 0.56 ± 0.09 mm, p = 0.08), but 
this finding was not statistically significant. As the 
analysis included a total of 55 persons, i.e., 17 with 
negative and 38 positive TPOabs, and p was close 
to statistical significance, we cannot confirm with 
certainty that the autoimmune etiology of SCH was 
not responsible for greater CIMT. Linear regression 
analysis did not show that positive TPOabs were in-
dependent predictors of CIMT and carotid plaques. 
However, the mechanism has yet to be clarified.
Besides TSH, triglycerides were also independent 
risk factors for mean CIMT. This study showed that 
patients with SCH have significantly higher concen-
trations of triglycerides. A meta-analysis (25) revea-
led that an increase in triglycerides of only 1 mmol/l 
increases the risk of cardiovascular disease by 76%. 
It is estimated that the values  of triglycerides abo-
ve 2.28 mmol/l and the ratio of total cholesterol/
HDL over 5, contribute with 25% of all cardiovascu-
lar events. Thus, despite TSH, serum concentrations 
of triglycerides in SCH were responsible for the fin-
ding of greater CIMT. Also, total cholesterol/HDL-
-C ratio, whose mean value was significantly higher 
in the SCH group, showed to be an independent 
predictor of carotid plaques. 
Hypertension is a major risk factor for carotid inti-
ma-media thickening. Meta-analysis of Wang and cols. 
(26) showed blood pressure values as independent fac-
tors for CIMT. Some studies (27,28) found higher va-
lues of diastolic blood pressure in patients with SCH. 
In the present study, diastolic blood pressure was an 
independent predictor of mean CIMT, but there 
was no difference between mean diastolic and sys-
tolic blood pressure in the studied groups. It is well 
known that aging increases blood pressure, as well as 
the incidence of SCH. The presence of both, diasto-
lic hypertension and SCH, will favor faster develop-
ment of atherosclerosis.  
The increased risk of atherosclerosis in patients 
with SCH is usually due to dyslipidemia and hyper-
tension (5), but the results of this study, similar to 
other ones (22,23,29), showed that SCH is asso-
ciated with carotid atherosclerosis independent of 
these factors. Several studies (17,18,30) showed a 
reduction in CIMT in patients with SCH after treat-
ment with levothyroxine. The present study showed 
a clear association between SCH and CIMT, prima-
rily because only young patients were included, who 
should in fact be a target group for atherosclerosis 
prevention. According to the results of the present 
study, to prevent or at least slow down the process of 
atherosclerosis in SCH, patients with SCH should be 
on thyroid replacement therapy. However, prospective 
studies are needed to confirm this statement.
In conclusion, our data revealed that SCH is associa-
ted with increased CIMT and presence of carotid plaques, 
independent of classical risk factors for atherosclerosis. 
Subclinical hypothyroidism and atherosclerosis
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